MarketWatch
The FDA declined to approve one of biotech’s most closely watched cancer drugs
Monday, November 16, 2026
The FDA declined to approve Summit Therapeutics' lung cancer drug, stating that the company must demonstrate the medication extends patient survival. Summit Therapeutics had submitted the drug for FDA review. The regulator's decision requires additional clinical data before reconsidering approval.
Original reporting:
